ChromaDex Corporation (CDXC) News

ChromaDex Corporation (CDXC): $1.67

-0.09 (-5.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CDXC to Watchlist
Sign Up

Industry: Chemicals


Ranked

of 89

in industry

Filter CDXC News Items

CDXC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CDXC News Highlights

  • CDXC's 30 day story count now stands at 3.
  • Over the past 22 days, the trend for CDXC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about CDXC are NR.

Latest CDXC News From Around the Web

Below are the latest news stories about ChromaDex Corp that investors may wish to consider to help them evaluate CDXC as an investment opportunity.

ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022

LOS ANGELES, February 22, 2022--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Yahoo | February 22, 2022

ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside

LOS ANGELES, February 09, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide (NAD) precursors. ChromaDex currently holds a robust patent portfolio of over 40 granted or licensed patents relating to Niagen® (patented NR) and other precursors to NAD, a molecule at the forefront of the healthy aging and cellular health categories. Niage

Yahoo | February 9, 2022

ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients

LOS ANGELES, January 31, 2022--ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program’s (CERP™) 100th published peer-reviewed study on the company’s flagship ingredient Niagen® (patented nicotinamide riboside, or "NR") and other proprietary ingredients. CERP, the program pioneering NR research, is the first-of-its-kind to reach such a milestone. The recently published preclinical trial in the Investigative Ophthalmology & Visual Science Journal investigated the effects

Yahoo | January 31, 2022

ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

LOS ANGELES, January 25, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or "NR") ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation. The study investigated the anti-inflammatory effects of ChromaDex’s proprietary NR ingredient in monocytes (a type of white blood cell) extracted from two groups: young, healthy subjects and patients diagnosed with system

Yahoo | January 25, 2022

We Think ChromaDex (NASDAQ:CDXC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | January 22, 2022

ChromaDex in pact with Designs for Health to offer new Niagen-formulated products

ChromaDex (CDXC) is trading ~2.5% higher in the pre-market after announcing a supply agreement with Designs for Health to offer new products formulated with Niagen.Accordingly, Designs

Seeking Alpha | January 20, 2022

ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements

ChromaDex Corp (NASDAQ: CDXC) has announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex's proprietary healthy aging ingredient Niagen will be added to multi-ingredient Designs for Health formulas. The Company says that Niagen is the world's first and only FDA-safety reviewed and patented form of nicotinamide riboside. The new products will be available exclusively through the Company's extensi

Yahoo | January 20, 2022

ChromaDex and Designs for Health Partner for New Product Development on Niagen®

LOS ANGELES, January 20, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex’s proprietary healthy aging ingredient Niagen®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas. The new products will be available exclusively through the company’s exte

Yahoo | January 20, 2022

How Much Of ChromaDex Corporation (NASDAQ:CDXC) Do Insiders Own?

The big shareholder groups in ChromaDex Corporation ( NASDAQ:CDXC ) have power over the company. Large companies...

Yahoo | December 8, 2021

Brokerages Expect ChromaDex Co. (NASDAQ:CDXC) Will Post Quarterly Sales of $18.53 Million

Equities analysts expect that ChromaDex Co. (NASDAQ:CDXC) will announce $18.53 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for ChromaDexs earnings, with the highest sales estimate coming in at $19.00 million and the lowest estimate coming in at $17.86 million. ChromaDex reported sales of $15.45 million during the []

Transcript Daily | December 7, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4966 seconds.